文献速递白血病

酪氨酸激酶抑制剂停药后慢性髓性白血病患者免疫识别的单细胞分析

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
PubMed 文献 · Leukemia · 2023-11-02

为研究慢性髓性白血病(CML)患者停用酪氨酸激酶抑制剂(TKI)后维持无治疗缓解(TFR)的免疫控制机制,对来自CML患者(n=13,N=25)、其他癌症患者(n=28)和健康人(n=7)的55份样本进行单细胞RNA和T细胞受体(TCR)测序分析。CML中自然杀伤(NK)细胞数量多且表型活跃,以CD56dim亚群为主,高表达GZMA/B、PRF1、CCL3/4和IFNG,并通过抑制性LGALS9-TIM3和PVR-TIGIT与白血病细胞相互作用;抗PR1 T细胞在CML中更常见、富集于骨髓和成熟细胞毒性CD8+ TEMRA亚群,尤其在维持TFR的患者中。

要点

  • CML患者NK细胞数量多且表型活跃,以CD56dim亚群为主,高表达GZMA/B、PRF1、CCL3/4和IFNG。
  • CML中NK细胞与白血病细胞通过抑制性LGALS9-TIM3和PVR-TIGIT相互作用,共培养后LGALS9和TIM3上调。
  • 抗PR1 T细胞在CML中更常见、富集于骨髓和CD8+ TEMRA亚群,尤其在维持TFR的患者中。

核心结论

  • 结果突显NK细胞和抗PR1 T细胞在CML抗白血病免疫反应中的作用。

研究设计与样本

  • 分析55份单细胞RNA和TCR测序样本(scRNA+TCRαβ-seq),来自CML患者(n=13,N=25)、其他癌症患者(n=28)和健康人(n=7)。
  • 创建分类器识别靶向白血病相关抗原PR1的TCR,并在90份CML和786份健康人TCRβ测序样本中定量抗PR1 T细胞。

主要发现

  • CML中NK细胞数量多且表型活跃,将其与健康人和其他癌症区分开。
  • CML中多数NK细胞属于活跃的CD56dim亚群,高表达GZMA/B、PRF1、CCL3/4和IFNG。
  • CML中NK细胞与白血病细胞通过抑制性LGALS9-TIM3和PVR-TIGIT相互作用;共培养后CML靶细胞LGALS9上调、NK细胞TIM3上调。
  • 抗PR1 T细胞在CML中更常见,富集于骨髓样本和成熟细胞毒性CD8+ TEMRA亚群,尤其在维持TFR的患者中。

关键数值与推荐

  • CML患者n=13(N=25),其他癌症患者n=28,健康人n=7,共55份scRNA+TCRαβ-seq样本。
  • 抗PR1 T细胞定量在90份CML和786份健康人TCRβ测序样本中进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunological control of residual leukemia cells is thought to occur in patients with chronic myeloid leukemia (CML) that maintain treatment-free remission (TFR) following tyrosine kinase inhibitor (TKI) discontinuation. To study this, we analyzed 55 single-cell RNA and T cell receptor (TCR) sequenced samples (scRNA+TCRαβ-seq) from patients with CML (n = 13, N = 25), other cancers (n = 28), and healthy (n = 7). The high number and active phenotype of natural killer (NK) cells in CML separated them from healthy and other cancers. Most NK cells in CML belonged to the active CD56dim cluster with high expression of GZMA/B, PRF1, CCL3/4, and IFNG, with interactions with leukemic cells via inhibitory LGALS9-TIM3 and PVR-TIGIT interactions. Accordingly, upregulation of LGALS9 was observed in CML target cells and TIM3 in NK cells when co-cultured together. Additionally, we created a classifier to identify TCRs targeting leukemia-associated antigen PR1 and quantified anti-PR1 T cells in 90 CML and 786 healthy TCRβ-sequenced samples. Anti-PR1 T cells were more prevalent in CML, enriched in bone marrow samples, and enriched in the mature, cytotoxic CD8 + TEMRA cluster, especially in a patient maintaining TFR. Our results highlight the role of NK cells and anti-PR1 T cells in anti-leukemic immune responses in CML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Huuhtanen J, Adnan-Awad S, Theodoropoulos J, et al. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 2023. PMID: 37919606. doi:10.1038/s41375-023-02074-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。